A new machine learning model tackles the biological noise threatening to derail non-invasive cancer testing.

Liquid biopsies promise to detect cancer from a simple blood draw, but the human body is incredibly noisy. As we age, our healthy white blood cells accumulate mutations that look identical to tumor DNA. This biological mimicry, known as clonal hematopoiesis, routinely triggers false alarms and treatment mismatches.

The current fix is too expensive. Clinicians must sequence both the patient’s blood plasma and their physical white blood cells to filter out the background noise. This doubles the cost and complexity of a supposedly simple test, stalling its widespread clinical adoption.

The Algorithmic Filter

A new model called plasmaCHORD bypasses this physical bottleneck. Instead of running a second sequencing test, the algorithm analyzes DNA fragment patterns, patient age, and mutation types to distinguish tumor DNA from white blood cell mutations.

It turns a costly hardware problem into a software solution.

The Clinical Reality

This shift is about economics as much as accuracy. If liquid biopsies remain prohibitively expensive due to double-sequencing, they will never become a routine tool for the masses. By using machine learning to predict the origin of mutations, oncology can drastically lower the cost of precision monitoring.

However, software-based filtering has limits. While the model shows high accuracy in trials, algorithms rely on probabilistic patterns rather than physical verification. Clinicians must decide what level of algorithmic uncertainty they are willing to accept before making high-stakes treatment decisions based on a digital prediction.